Vyzulta, indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension, is now being distributed by Bausch + Lomb to U.S. wholesale pharmaceutical distributors.
Vyzulta (latanoprostene bunod ophthalmic solution 0.024%) is the first prostaglandin analogue with one of its metabolites being nitric oxide, according to a press release from Valeant Pharmaceuticals.
The drug will be available to patients in the next several days.
“We’re excited that Vyzulta is now available as a treatment option for people suffering from glaucoma,” Joseph C. Papa,
Uncategorized